Product
Arsenic trioxide
Aliases
ATO
2 clinical trials
4 indications
Indication
Pediatric CancerIndication
Li-Fraumeni syndromeIndication
TP53 MutationsIndication
Acute Promyelocytic LeukemiaClinical trial
Clinical Research on Efficacy and Safety of Arsenic Trioxide Combined With Chemotherapy in p53-mutated Pediatric Cancer Patients:A Prospective,Single-arm, Multi-center StudyStatus: Recruiting, Estimated PCD: 2031-12-14
Clinical trial
A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2025-01-01